# An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

> **NCT00580801** · PHASE2 · COMPLETED · sponsor: **Tibotec BVBA** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Pegylated-interferon-alfa-2a
- **DRUG:** Placebo
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00580801
- **Lead sponsor:** Tibotec BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580801, "An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00580801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*